肝细胞癌
HBx公司
天冬酰胺合成酶
癌变
癌症研究
天冬酰胺
肝癌
下调和上调
PI3K/AKT/mTOR通路
肿瘤进展
癌症
生物
医学
内科学
信号转导
基因
乙型肝炎病毒
免疫学
生物化学
病毒
酶
作者
Qi Zhou,Leijia Li,Feifei Sha,Yiming Lei,Xuan Tian,Lingjun Chen,Yan Chen,Huiling Liu,Yunwei Guo
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2023-05-09
卷期号:83 (14): 2372-2386
被引量:17
标识
DOI:10.1158/0008-5472.can-22-3561
摘要
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and has a poor prognosis. Pituitary tumor transforming gene 1 (PTTG1) is highly expressed in HCC, suggesting it could play an important role in hepatocellular carcinogenesis. Here, we evaluated the impact of PTTG1 deficiency on HCC development using a diethylnitrosamine (DEN)-induced HCC mouse model and a hepatitis B virus (HBV) regulatory X protein (HBx)-induced spontaneous HCC mouse model. PTTG1 deficiency significantly suppressed DEN- and HBx-induced hepatocellular carcinogenesis. Mechanistically, PTTG1 promoted asparagine synthetase (ASNS) transcription by binding to its promoter, and asparagine (Asn) levels were correspondingly increased. The elevated levels of Asn subsequently activated the mTOR pathway to facilitate HCC progression. In addition, asparaginase treatment reversed the proliferation induced by PTTG1 overexpression. Furthermore, HBx promoted ASNS and Asn metabolism by upregulating PTTG1 expression. Overall, PTTG1 is involved in the reprogramming of Asn metabolism to promote HCC progression and may serve as a therapeutic and diagnostic target for HCC.PTTG1 is upregulated in hepatocellular carcinoma and increases asparagine production to stimulate mTOR activity and promote tumor progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI